Overview
- Researchers presented data at the ASCO Genitourinary Cancers Symposium from 58 men with treatment‑resistant disease.
- Tumor shrinkage was reported in roughly 45% of participants.
- In the highest‑dose group of 17 patients, 53% saw a 90% PSA decline and 82% had PSA levels cut by half.
- Reported side-effects were mostly mild, with 88% experiencing only very mild symptoms.
- VIR‑5500 is a tumor‑activated T‑cell engager with a cloaking design; the Vir Biotechnology–funded, early‑phase results now move to larger, confirmatory trials.